Experimental drug aims to boost blood health in thalassemia patients
NCT ID NCT03692052
Summary
This study tested whether the drug AG-348 could safely increase hemoglobin levels in adults with a less severe form of thalassemia who don't regularly need blood transfusions. Twenty participants took the drug twice daily for up to 24 weeks, with the option to continue in a long-term follow-up study for up to 10 years. The main goal was to see if the treatment could raise hemoglobin by a specific amount.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust (Hammersmith Hospital)
London, W12 0HS, United Kingdom
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
-
University Health Network (Toronto General Hospital)
Toronto, Ontario, M5G 2C4, Canada
Conditions
Explore the condition pages connected to this study.